Association Between Primary Care Supply and Population Morbidity and Mortality in France at the Territorial Level (M-OSP)

March 30, 2026 updated by: MSPU de Pins-Justaret

The M-OSP study investigates the association between the density of primary care professionals, including general practitioners (GPs), and population-level health outcomes across 2,850 life-health territories in France. Evidence from several OECD countries suggests higher GP density may reduce mortality, particularly cause-specific mortality such as cardiovascular deaths, but uncertainties remain regarding generalizability and other health outcomes.

This cross-sectional epidemiological study uses aggregated, territory-level data from 2009-2022, including: mortality rates (age- and sex-standardized), hospitalizations (MCO), emergency department visits, and the distribution of primary care professionals and facilities (GPs, nurses, physiotherapists, dentists, midwives, gynecologists, pediatricians, psychiatrists, and community pharmacies).

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

7000000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Population-wide study

Description

Inclusion Criteria:

All individuals affiliated with any French health insurance scheme and recorded in the Système National des Données de Santé (SNDS; French National Health Data System) through the Datamart de Consommation Inter-Régimes (DCIR; French national health insurance claims database) between January 1, 2009 and December 31, 2022

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality rate
Time Frame: 1 year
Yearly mortality rate, standardized by age group and sex
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

MSPU de Pins-Justaret

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

September 30, 2026

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

January 23, 2026

First Submitted That Met QC Criteria

March 30, 2026

First Posted (Actual)

April 2, 2026

Study Record Updates

Last Update Posted (Actual)

April 2, 2026

Last Update Submitted That Met QC Criteria

March 30, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • M-OSP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mortality

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe